Promising Biology. Investable Asset.

Most manufacturing plans are evaluated in pieces: the process in one place, the economics in another, regulatory expectations later. We look at all of it together, because a change in one shifts the others.

The harder the product is to make e.g. complex modalities and advanced therapies, the more it matters.


The production plan looks fine until it is executed.

Chirasoph was built to address that.

We focus on evaluating assets in the pre-Phase II window — where processes aren’t locked in, manufacturing risks can still be assessed and decisions can still be reversed.

64%

— Accenture

40%

— BioProcess International

+3.5 years

— Chirasoph’s internal analysis


Our analysis runs on tools we are building in-house.

01

ORYX

02

IBEX

03

TAHR


Built for the people
making high-stakes decisions

Investors & BD Teams

Biotech & CDMO


Dr. Setu Kasera, Independent Consultant. Setu is a chemist by training and her background combines R&D finance and technical due diligence for investors, CMC and techno economic assessments, and development of regulatory-grade automated systems for complex processes. She holds a PhD and MPhil in Chemistry from the University of Cambridge, UK and is currently based in Germany.

Dr. Javier Varela, PhD, Independent Associate Consultant. Javier is a microbiologist and metabolic engineer with more than ten years hands-on experience in biotechnology, including pilot-scale fermentation and industrial strain engineering. He holds a PhD in Microbiology from University of Cork, Ireland and MSc Biochemistry from Universidad de Santiago de Chile, and is currently based in Chile.


Schedule an initial review.

We will not share your details with any third parties.